Obinutuzumab Delays Disease Progression in CLL Monthly Prescribing Reference ... obinutuzumab (GA101) plus chlorambucil helped patients with previously untreated chronic lymphocytic leukema live significantly longer without their disease worsening (progression-free survival; PFS) compared to Rituxan (rituximab) plus chlorambucil. Roche antibody tops Rituxan in blood cancer CLL Genentech Trumpets Phase III Results for CLL Candidate |
